Get the Stockscreener App
67.43
1.00%
-0.7561
Nuvalent Inc stock is traded at $67.43, with a volume of 306.47K.
It is down -1.00% in the last 24 hours and up +4.38% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$68.19
Open:
$68.66
24h Volume:
306.47K
Relative Volume:
0.56
Market Cap:
$5.45B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-17.29
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
-12.04%
1M Performance:
+4.38%
6M Performance:
-28.25%
1Y Performance:
-1.65%
1-Day Range:
$66.17
$69.20
1-Week Range:
$66.17
$78.97
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
67.45 | 5.45B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.19 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.20 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
620.01 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.96 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.25 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Financial Health Check: Examining Nuvalent Inc (NUVL)’s Key Ratios - DWinneX
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Lowered by Envestnet Asset Management Inc. - Defense World
When the Price of (NUVL) Talks, People Listen - news.stocktradersdaily.com
Nuvalent Inc (NUVL) looking to reclaim success with recent performance - Sete News
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results - Seeking Alpha
Nuvalent reveals preclinical data on cancer drug zidesamtinib - Investing.com
Nuvalent Announces Publication in Molecular Cancer Therapeutics - GuruFocus
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Nuvalent, Inc. (NASDAQ:NUVL) Position Boosted by Wells Fargo & Company MN - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting - ADVFN
Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Nuvalent describes new ROS and ALK tyrosine kinase receptor inhibitors - BioWorld MedTech
UBS gives a Buy recommendation for Nuvalent Inc (NUVL) - knoxdaily.com
JPMorgan Chase & Co. Acquires 47,818 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Trend Tracker for (NUVL) - news.stocktradersdaily.com
Nuvalent Board Member Resigns, Joins Advisory Board - TipRanks
Alliancebernstein L.P. Purchases 500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Commonwealth Equity Services LLC Raises Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Sei Investments Co. Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent: Cannot Make Sense Of The Valuation - Seeking Alpha
Nuvalent stock touches 52-week low at $61.75 amid market shifts By Investing.com - Investing.com South Africa
Nuvalent stock touches 52-week low at $61.75 amid market shifts - Investing.com Australia
Norges Bank Invests $24.95 Million in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
KLP Kapitalforvaltning AS Buys New Shares in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib - Onco'Zine
Commit To Purchase Nuvalent At $55, Earn 11.9% Annualized Using Options - Nasdaq
(NUVL) On The My Stocks Page - news.stocktradersdaily.com
Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? - Yahoo
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Quantisnow
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Stake Cut by Virtu Financial LLC - MarketBeat
Teacher Retirement System of Texas Boosts Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Nuvalent chief development officer sells shares worth $292,468 By Investing.com - Investing.com Philippines
10 Best Debt Free Mid Cap Stocks to Buy Now - Insider Monkey
Nuvalent chief development officer sells shares worth $292,468 - Investing.com India
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 - Nasdaq
Breakthrough Cancer Drug Data: New Brain-Penetrant Therapy Shows Promise Against Resistant Tumors - Stock Titan
Recent Insider Activity Suggests Potential Gains for Nuvalent Inc (NUVL) - knoxdaily.com
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Raymond James Financial Inc. Acquires Shares of 133,964 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 18,609 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - The AM Reporter
Nuvalent CEO Porter sells $2.05 million in stock By Investing.com - Investing.com Australia
Nuvalent CEO Porter sells $2.05 million in stock - Investing.com
Victory Capital Management Inc. Cuts Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Charles Schwab Investment Management Inc. Buys 7,742 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
US Bancorp DE Invests $90,000 in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Noci Darlene | Chief Development Officer |
Apr 29 '25 |
Sale |
74.56 |
4,000 |
298,240 |
48,034 |
| Porter James Richard | President and CEO |
Apr 15 '25 |
Option Exercise |
27.85 |
27,000 |
751,950 |
276,062 |
| Porter James Richard | President and CEO |
Apr 15 '25 |
Sale |
68.94 |
27,000 |
1,861,504 |
249,062 |
1.86%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):